Illumina makes next-generation sequencers. That is its thing.
But in a few years, the biotech darling of San Diego, California, hopes to have advanced beyond that label, rounding out its product and service offerings with sophisticated diagnostics and clinically-validated tools.
On Monday the company reinforced that mission with the launch of a new tumor profiling panel, TruSight Tumor 170, which it calls a robust and scalable platform geared towards the future of cancer research and care.
